MX2021011147A - Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas. - Google Patents

Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas.

Info

Publication number
MX2021011147A
MX2021011147A MX2021011147A MX2021011147A MX2021011147A MX 2021011147 A MX2021011147 A MX 2021011147A MX 2021011147 A MX2021011147 A MX 2021011147A MX 2021011147 A MX2021011147 A MX 2021011147A MX 2021011147 A MX2021011147 A MX 2021011147A
Authority
MX
Mexico
Prior art keywords
biofilms
prevention
methods
materials
enhanced treatment
Prior art date
Application number
MX2021011147A
Other languages
English (en)
Inventor
Sean Farmer
Ken Alibek
Original Assignee
Locus Ip Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Ip Co Llc filed Critical Locus Ip Co Llc
Publication of MX2021011147A publication Critical patent/MX2021011147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invención en cuestión proporciona materiales y método para prevenir, inhibir o reducir la formación de biopelículas e infecciones por biopelículas. La invención utiliza subproductos del crecimiento de microorganismos benéficos para aumentar la eficacia de sustancias biocidas en el tratamiento, disrupción y/o prevención de biopelículas. De manera ventajosa, la invención en cuestión es útil contra cepas de bacterias resistentes a antibióticos, tal como MRSA y ciertas cepas de Helicobacter pylori.
MX2021011147A 2019-03-15 2020-03-13 Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas. MX2021011147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819000P 2019-03-15 2019-03-15
US201962846079P 2019-05-10 2019-05-10
PCT/US2020/022591 WO2020190699A1 (en) 2019-03-15 2020-03-13 Materials and methods for enhanced treatment and prevention of biofilms

Publications (1)

Publication Number Publication Date
MX2021011147A true MX2021011147A (es) 2021-10-22

Family

ID=72520453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011147A MX2021011147A (es) 2019-03-15 2020-03-13 Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas.

Country Status (12)

Country Link
US (1) US20220142988A1 (es)
EP (1) EP3937634A4 (es)
JP (1) JP2022525762A (es)
KR (1) KR20210129725A (es)
CN (1) CN113873883A (es)
AU (1) AU2020241243A1 (es)
BR (1) BR112021018306A2 (es)
CA (1) CA3132821A1 (es)
IL (1) IL286437A (es)
MX (1) MX2021011147A (es)
SG (1) SG11202109097UA (es)
WO (1) WO2020190699A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212754A1 (en) * 2021-03-26 2022-09-29 Michael Fefer Antibiofilm formulations comprising a polycarboxylic acid derivative, an essential oil, and a select biosurfactant
CN117838736B (zh) * 2024-01-29 2024-06-14 吉林省农业科学院(中国农业科技东北创新中心) 凝结芽孢杆菌ja845在制备预防和/或治疗抗动脉粥样硬化药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI103056B (fi) * 1996-08-16 1999-04-15 Orion Yhtymae Oy Menetelmä ja testipakkaus näytteenottopinnan esikäsittelemiseksi
US20020123077A1 (en) * 2000-09-29 2002-09-05 O'toole George A. Novel compounds capable of modulating biofilms
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
JP2012072179A (ja) * 2005-08-30 2012-04-12 Kao Corp バイオフィルム抑制剤
EP2273989A4 (en) * 2008-04-07 2013-05-01 Interface Biologics Inc POLYTHERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS
WO2010067245A1 (en) * 2008-12-10 2010-06-17 Pan-Eco S.A. Biosurfactant composition produced by a new bacillus licheniformis strain, uses and products thereof
US9028878B2 (en) * 2009-02-03 2015-05-12 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
WO2011088020A2 (en) * 2010-01-12 2011-07-21 The General Hospital Corporation Modified saponins for the treatment of fungal infections
US20110306569A1 (en) * 2010-06-11 2011-12-15 Oregon State University Rhamnolipid biosurfactant from pseudomonas aeruginosa strain ny3 and methods of use
EP2951311A4 (en) * 2013-02-02 2016-07-13 Synthezyme Llc COMBINATIONS OF MODIFIED SOPHOROLIPIDS AS ANTIMICROBIAL AGENTS
CN104233331B (zh) * 2014-09-11 2016-06-29 南京农业大学 食品不锈钢加工器械表面致病菌生物菌膜的清除方法
WO2018201119A1 (en) * 2017-04-29 2018-11-01 Nevada Naturals Inc. Biofilm penetrating compositions and methods

Also Published As

Publication number Publication date
JP2022525762A (ja) 2022-05-19
BR112021018306A2 (pt) 2022-01-25
EP3937634A4 (en) 2022-11-09
SG11202109097UA (en) 2021-09-29
AU2020241243A1 (en) 2021-09-09
CA3132821A1 (en) 2020-09-24
IL286437A (en) 2021-10-31
US20220142988A1 (en) 2022-05-12
EP3937634A1 (en) 2022-01-19
KR20210129725A (ko) 2021-10-28
WO2020190699A1 (en) 2020-09-24
CN113873883A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
MX2021013663A (es) Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopeliculas.
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
GB201013307D0 (en) Anti-microbial metal organic framework
GB2547402A (en) Prevention and treatment of microbial infections
MX2010007823A (es) Inhibidores de beta-lactamasa.
PH12017500852A1 (en) Combination therapy for treatment of resistant bacterial infections
WO2009126502A3 (en) Methods of inhibiting and treating biofilms using glycopeptide antibiotics
WO2020149756A3 (en) Chitosan-based nanocomposite as an antimicrobial agent and corrosion inhibitor
WO2008111719A8 (en) Bacillus amyloliquefaciens k317 for suppressing the growth of antibiotics-resistant pathogenic microorganism or enteropathogenic microorganism
MX2021011147A (es) Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas.
MX2017008563A (es) Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga.
MX2023000736A (es) Productos microbianos alimentados en directo.
MX2020012263A (es) Compuestos antibacterianos.
WO2015100331A3 (en) Phenazine derivatives as antimicrobial agents
MX2017008562A (es) Novedoso bacteriófago de e. coli enteroinvasiva esc-cop-4 y su uso para inhibir la proliferación de e. coli enteroinvasiva.
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
NZ610396A (en) Use of chelating agent and peptide antimicrobial compounds
MX2022006109A (es) Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa.
AU2012335397A8 (en) Novel bacteriophages
MX2022008631A (es) Cepas de bacillus con capacidad de degradar compuestos de nitrogeno inorganico.
WO2010123599A3 (en) Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
MX2009006808A (es) Eliminacion e inhibicion del crecimiento del estafilococo aureus resistente a la meticilina mediante bacterias del acido lactico.
MX2021003598A (es) Microorganismos para la inhibicion de patogenos vegetales.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MY197563A (en) Kimchi for preventing or treating helicobacter pylori-associated diseases